The week that turned the cancer immunotherapy market on its head – pharmaphorum
pharmaphorum |
The week that turned the cancer immunotherapy market on its head
pharmaphorum This week may have produced a seismic shift in cancer immunotherapy as serious doubts emerged about Roche's main contender, while solid phase 3 results boosted investor confidence in a late-to-market rival from AstraZeneca. Just days after a late-stage … AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next Key AstraZeneca drug shown to reduce risk of death from lung cancer FTSE 100 boosted by AstraZeneca rise |
